Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
- Study ID
- NCT00435955
- Phase
- PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- High dose chemotherapy with autologous transplantation — PROCEDURE
- Rituximab — DRUG
Study Details
The purpose of this study is to determine whether an intensified treatment plus Rituximab followed by autologous transplantation is superior to a conventional chemotherapy regimen also supplemented with Rituximab.
Key Dates
- Start date
- Mar 31, 2000
- Status verified
- Feb 2007
Study Design
- Enrollment
- 240 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Event free survival at three years
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular LymphomaPHASE2 · Not Yet Recruiting · XEME Biopharma Inc. · Newnan, Georgia
- Clonal Evolution in Follicular LymphomaRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota